PrimeRFP SCOUT · Federal Contract Recompete Brief

36C26022F0281Pegloticase (krystexxa) 8mg ML 75987-0080-10 — Horizon Therapeutics Usa, Inc

The prior award was single-bid — competitive dynamics may favor a challenge. PoP ended Nov 30, 2022 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

260-Network Contract Office 20 (36C260)

Awarding office

Horizon Therapeutics Usa, Inc

Recipient

Nov 30, 2022

PoP end

$199K

Obligated

$199K

Potential

325412

NAICS

6505

PSC

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Horizon Therapeutics Usa, Inc — $90

Contract facts

Federal

Contract number36C26022F0281

Also listed as36C260-22-F-0281

Also listed as36F79719D0224-36C26022F0281

Agency260-Network Contract Office 20 (36C260)

Awarding office260-Network Contract Office 20 (36C260)

Awarding agencyDepartment of Veterans Affairs (VA)

Funding agencyDepartment of Veterans Affairs (VA)

IncumbentHorizon Therapeutics Usa, Inc

CAGE6TDL9

UEISK1UK7S74GB3

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDV36F79719D0224

Place of performanceDEERFIELD IL

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition

PoP startJun 1, 2022

PoP end (current)Nov 30, 2022

Obligated$199K

Current value$199K

Potential value$199K

PEGLOTICASE (KRYSTEXXA) 8MG/ML 75987-0080-10 is a federal award for 260-Network Contract Office 20 (36C260) held by Horizon Therapeutics Usa, Inc. Estimated value $199K ($199K obligated). Current period of performance ends Nov 30, 2022. Last award drew 1 bidder. Place of performance: DEERFIELD IL.

PEGLOTICASE (KRYSTEXXA) 8MG/ML 75987-0080-10

Recompete timing

Public

● Past PoP end (1360 days ago)

Current PoP ended Nov 30, 2022 (1360 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 36C26022F0281?

36C26022F0281 (Pegloticase (krystexxa) 8mg ML 75987-0080-10) is a 260-Network Contract Office 20 (36C260) award with a potential value of $199K, currently held by Horizon Therapeutics Usa, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is 36C260-22-F-0281?

36C260-22-F-0281 is the dashed form of PIID 36C26022F0281 (Pegloticase (krystexxa) 8mg ML 75987-0080-10), held by Horizon Therapeutics Usa, Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded 36C26022F0281?

260-Network Contract Office 20 (36C260) awarded 36C26022F0281 to Horizon Therapeutics Usa, Inc (potential $199K).

Who is the incumbent on 36C26022F0281?

Horizon Therapeutics Usa, Inc is the incumbent. The current period of performance ends Nov 30, 2022.

When does Horizon Therapeutics Usa, Inc’s 36C26022F0281 come up for recompete?

SCOUT tracks a period-of-performance end of Nov 30, 2022. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of May 20, 2022 · refreshed monthly